Free Trial

Top 8 Companies That Are Adapting to a Post-Coronavirus World - 7 of 8

 
 

#7 - Teladoc Health (NYSE:TDOC)

Moments in time, such as the coronavirus pandemic, can serve as tipping points for companies like Teladoc Health (NYSE:TDOC) . A behavior that is ingrained in our psyche since we were children is if you are sick, you go to the doctor. However, the level of contagion of the coronavirus is causing many thoughtful consumers to question this tried-and-true doctrine. After all, why go to the doctor, if your presence alone could infect other patients?

However, the common-sense idea of a doctor making a technology-assisted house call was not possible either due to a lack of willingness by doctors, or skepticism by patients. In that regard, the coronavirus is creating a perfect storm.

In an interview with CNBC’s Jim Cramer, Jason Gorevic, Teladoc’s CEO said, “The demand has shifted forever on virtual care, and we’re on the verge of a new era for virtual care in the healthcare system.”

But the revolution will still take time. Only a fraction of states are currently expanding their telehealth services. But one state, Washington, is taking the unique approach of allowing doctors to treat patients even if the physician is licensed in another state (they must be licensed elsewhere).

Teladoc is not yet profitable. But with momentum from patients, physicians, and it appears the federal government, this may be its moment in time. As of the close of trading on March 27, Teladoc stock was up over 90% in 2020.



About Teladoc Health

Teladoc Health, Inc provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems. Read More 
Current Price
$9.44
Consensus Rating
Hold
Ratings Breakdown
7 Buy Ratings, 14 Hold Ratings, 0 Sell Ratings.
Consensus Price Target
$12.24 (29.6% Upside)

 

We recommended Palantir in 2021, now we’re recommending this... (Ad)

My research indicates there is only one investment that can meet AI's unprecedented demand for energy.

Click to get the name and ticker symbol